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Introduction
Spinal cord stimulation(SCS) is an adjustable, non-destructive, neuromodulatory
procedure which delivers therapeutic doses of electrical current to the spinal cord for the
management of neuropathic pain. The most common indications include postlaminectomy syndrome, complex regional pain syndrome (CRPS), ischemic limb pain,
and angina. Scattered reports regarding the treatment of intractable pain due to other
causes including visceral/abdominal pain, cervical neuritis pain, spinal cord injury pain,
post-herpetic neuralgia, and neurogenic thoracic outlet syndrome have also appeared in
the literature. The procedures are most commonly performed by neurosurgeons or
anesthesiologists specializing in pain management1-3 but other specialties, such as
rehabilitation medicine and orthopedic surgery, have also demonstrated interest in the
procedure.
The enthusiasm with SCS began with the introduction of the gate control theory for pain
control by Melzack and Wall4 in 1965. They noted that stimulation of large myelinated
fibers of peripheral nerves resulted in paresthesias and blocked the activity in small
nociceptive projections. In 1967, Shealy, inserted the first dorsal column stimulator in a
human suffering from terminal metastatic cancer5,6.. Subsequently, electrodes have been
implanted utilizing a variety of techniques: via a laminectomy in the subarachnoid space6,
between the two layers of the dura or in the epidural space, in either dorsal or ventral to
the spinal cord.7-9. Subsequently, less invasive percutaneous techniques were
introduced.10.
Great advances in technology has also driven the popularity of the field. The electrodes
were initially all unipolar and bipolar arrays developed subsequently. Furthermore, the
contact combinations could only be hardwired, and could not be reprogrammed after the
pulse generator was implanted. In the beginning, only radio-frequency (RF) driven
passive receivers were available. In the mid-seventies, the first implantable pulse
generator powered by a lithium battery was introduced into the market. In 1980, the first
percutaneous quadripolar electrode was produced and this could be reprogrammed non-

invasively through an external transmitter11. Subsequently, implantable pulse generators
(IPG) which can be both transcutaneusly charged and programmed have been developed.
This most recent advance is now leading a renewed interest in the utility of using special
electrode arrays in the delivery of electrical stimulation to the spinal cord.

Mechanisms of Action
Although a large body of work has been published, the exact mechanisms of action of
SCS remain unclear. The computer modeling work of Holsheimer, Coburn, and Strujik,
have shed some light, at least theoretically, on the distribution of the electrical fields
within the spinal structures12-17 It is clear that stimulation on the dorsal aspect of the
epidural space creates complex electrical fields which affect a large number of structures.
We do not know whether activating afferents within the peripheral nerve, dorsal columns,
or supra-lemniscal pathways share equivalent mechanisms of action. Additionally, there
may be antidromic action potentials passing caudally in the dorsal columns to activate
spinal segmental mechanisms in the dorsal horns as well as action potentials ascending in
the dorsal columns activating cells in the brainstem, which in turn might drive descending
inhibition. At the chemical level, animal studies suggest that the SCS triggers the release
of serotonin, substance P, and GABA within the dorsal horn.18-20
.
Indications
SCS has been used for a variety of pain conditions and is particularly indicated for pain
of neuropathic origin, including post-laminectomy syndrome, complex regional pain
syndrome, phantom limb pain, spinal cord injury pain, and interstitial cystitis. The
indications have extended to include the treatment of intractable pain due to abdominal or
visceral pain, and neurogenic thoracic outlet syndrome. SCS has been successfully
utilized to treat severe pain due to ischemic disease of the lower extremities and more
recently, intractable angina pain. Experience suggests that, in selected patients, SCS can

produce at least 50% pain relief in 50-60% of the implanted patients. Interestingly, with
the proper follow-up care, these results can be maintained over several years.
Complex Regional Pain Syndrome (CRPS)
The implementation of SCS in individuals with CRPS type I is more difficult than with
any other patients groups. The possibility of aggravating the original pain or causing a
new pain/allodynia at the implanted hardware site is greater than with any other
diagnostic category mentioned. The pain may spreads to other body parts and it is
challenging to be able to cover all the affected areas with stimulation.
In 1989, Barolat et al. reported reduction of pain in ten out of thirteen patients implanted.
No patients in that series were made pain free but all ten reported a definitive difference
when the stimulation was stopped21. In 1997, Kumar et al. presented a median follow-up
of 41 months on twelve patients with permanently implanted leads22. Eight patients
reported near complete resolution of their symptoms and four also maintained good
relief.
Kemler et al., in another series, reported 23 additional cases with 78% of the patients
reporting improvement23. In 2000, Kemler et al. published on a series of 54 patients who
either underwent randomization to SCS with physical therapy or physical therapy alone24.
In the SCS group, 67% patients experienced significant pain relief which persisted at 6
months. A 2.4 cm decrease and improvement in VAS was noted in the SCS group
compared with 0.2 cm increase in the physical therapy group. However, no functional
improvement was observed in either group. In 2006, in a letter to the editor of NEJM,
Kemler, recounted their five year follow-up on the patients with SCS. Their major
conclusion was that the effects of SCS diminished over time for these patients. In this
letter, they do not specify how reprogramming or modern devices might impact on the
long term effects of SCS therapy25.
Oakley and Weiner reported a prospective study of 19 patients with CRPS implanted
with spinal cord stimulation systems26. Of the 10 patients in whom detailed long–term

efficacy data was available, 3 reported full relief from their pain and 7 partial beneficial
relief.
Three additional prospective studies without matched controls have been reported (total
of 50 subjects) 26-28. Two of the studies reported success rates with an 84% overall
success rate. The third study by Calvillo et al27, reported a significant improvement in
pain scores (VAS) and a >50% reduction in narcotic use by 44% of subjects. In eight
retrospective studies the overall success rate was 84% (192 patients)29.
Post-laminectomy syndrome (also called Failed back surgery syndrome – FBSS)
Post-laminectomy syndrome is vaguely defined. The term has included pain localized to
the center of the lower lumbar area, pain in the buttocks, persistent radicular pain, or
diffuse lower extremity(s) pain. Arachnoiditis, epidural fibrosis, radiculitis,
microinstability, recurrent disk herniations, infections, have been perpetrated in the
etiology of this syndrome. Most published series distinguish between back and leg pain,
but the details of the pain syndromes are seldom defined. SCS is accepted in the
treatment of leg pain, but its widespread use for relief of pain in the lower lumbar area
still remains to be defined.
A great challenge, in the treatment of post-laminectomy syndrome, has been to obtain
stimulation in the low back. Even with direct stimulation to the low back, the pattern of
paresthesia is often replaced in time by an unpleasant segmental band of stimulation from
the thoracic roots, which negates the benefits of the procedure. Previous pioneering work
by Jay Law30,31 has shown that stimulation in the low back can be obtained only if one
uses multiple arrays of closely spaced bipoles at T9-T10. North et al. has challenged the
concept of the superiority of centered dual electrodes by showing that one single
quadripolar electrode in midline has the ability to stimulate the axial low back32. These
were acute observations, and no data exist as to the long-term behavior of single versus
dual electrodes. The advent of the tripole electrodes and the ability to steer current has
made it more plausible to aim for low back paresthesia. Further, flanking the cathode by
lateral anodes also appears to increase the discomfort threshold theoretically 33.

Marchand et al. 34 conducted a prospective randomized controlled study examining
patients with at least one prior surgery for chronic back pain secondary to trauma. Each
patient used a SCS and acted as their own control. Although a small trial, with only eight
patients pain, scores were significantly reduced with SCS compared to placebo
stimulation.
The longitudinal studies by North showed that in patients with post-surgical lumbar
arachnoid or epidural fibrosis without surgically remediable lesions, SCS is superior to
repeated surgical interventions on the lumbar spine (for back and leg pain) and to dorsal
ganglionectomy (for leg pain) 35. That study comprised 50 patients with a postlaminectomy syndrome who averaged 3.1 operations prior to SCS implantation.
Successful outcome (at least 50% pain relief and patient satisfaction with the result) was
obtained in 53% of patients at 2.2 years. Systematic review of the literature was
conducted by Turner, 199536. They reviewed a total of 41 articles from 1966 to 1994 that
met their criteria. It was noted that approximately 50-60% of patients with postlaminectomy greater than 50% pain relief was attained from the use of SCS. In 1996,
Burchiel et al conducted a prospective multi-center study with one year follow-up and
also reported 55% successful stimulation37. Medication usage and work status were not
changed significantly.
North et al. also conducted a prospective study randomizing patients with FBSS to either
repeat back surgery or SCS surgery 38. Patients were allowed to crossover after six
months. Ten of fifteen patients crossed over from back surgery to SCS, while only two of
twelve patients crossed over from SCS to back surgery.
Studies do not routinely differentiate between axial back and leg pain. Although there is
some recent data on back pain, it is still inconclusive. Most implanting physicians share
the experience that SCS is far more effective for radicular pain than for axial low back
pain.

Angina
The role of SCS in the management of refractory angina pectoris seems to be a very
promising. There are well documented reports in the literature revealing uniformly good
results in the relief of anginal pain39-43. Further, the results have been maintained in long
term follow-up and have been substantiated by a reduction in the intake of nitrates as
well. Interestingly, other findings have supported the evidence that SCS has effects that
go beyond pain relief. The observations that there is less ST segment depression and that
the exercise capacity, the time to angina and the recovery time all improve with
stimulation may suggest that there is a reduction in ischemia. In a positron emission
tomography study, a redistribution of myocardial flow in favor of ischemic parts of the
myocardium has been demonstrated as a long term effect of spinal cord stimulation, both
at rest and after pharmacologic stress induction44.
Vulink et al. conducted a prospective study on quality of life changes in patients with
refractory angina pectoris implanted with SCS. They found that both the pain and the
health aspects of quality of life improved significantly after 3 months of SCS. Further,
social, mental and physical aspects of quality of life were found improved after one year
of SCS45.
Hautvast et al. 46 implanted SCS in patients with stable angina pectoris and randomized
them. One group’s remained inactivated while the other group was instructed to use the
stimulator three times per day for one hour and with any angina attack. At 6 weeks,
compared with controls, the treatment group had increased exercise duration and time to
angina, and decreased anginal attacks and sublingual nitrate consumption. Also, observed
was a decrease in ischemic episodes on EKG, as well as a decrease in observed ST
segment depressions on exercise EKG. There was an increase in perceived quality of life
and decrease in pain. It was shown that a placebo effect from surgery in the treatment
group was unlikely because all patients had implantation surgery at baseline.
Mannheimer et al. 47 randomized 104 patients accepted for CABG to receive either
CABG (n=51) or SCS (n=53) in the ESBY study. This study demonstrated that patients

randomized to SCS showed a greater than 30% improvement in NHP scores(Nottingham
Health Profile) compared with baseline, which was significant and comparable to the
improvement shown by patients randomized to CABG48. These results were consistent on
follow up after 4 years. It is important to know that the 5 year mortality of 27.9% in the
ESBY study was similar between those receiving SCS and those who received CABG,
with no difference in the percentage of cardiac deaths. The ESBY study showed that
cardiac events were similar across the groups, but that there was significantly more
cerebrovascular events obsevered in the CABG group.
Both groups experienced a significant reduction in both the number of angina attacks and
the consumption of nitrates. There was no significant intergroup difference regarding
these parameters. In another prospective study of 104 patients who underwent SCS
implantation for refractory angina pectoris there was a significant decrease in angina
episodes at rest, angina episodes with activity, and total angina episodes49.
DeJongste et al. 41, randomized seventeen patients with angina to an active treatment
group (i.e. SCS implantation) and a control group. The control group was followed for
two months followed by SCS implantation. Both groups were followed for a total of 12
months. This study also revealed a significant reduction in the incidence of angina
attacks and in the consumption of nitrates (p<0.05).
Five additional studies are reported to be prospective but without matched controls45,50-53.
Each of these revealed significant benefit from spinal cord stimulation. The benefit
indices ranged from reduction in angina attacks, decrease nitrate consumption, decrease
in NYHA grade and improvement in NHP grade.
The concern whether stimulation can conceal an acute myocardial infarction was
addressed by Andersen et al. They reported on 3 out of 45 patients treated with SCS for
anginal pain who survived a myocardial infarction54. All three patients noticed the pain
to be different and unrelieved with SCS and all patients correctly guessed that the pain
was due to a myocardial infarction. The authors concluded that SCS for treatment of
anginal pain does not seem to conceal acute myocardial infarction. Anderson followed

this up in 1994 further concluding that neurostimulation does not conceal the pain of an
acute myocardial infarction55 . Particularly, SCS reduces the severity of anginal attack but
was unable to suppress the conduction and perception of cardiac pain signals which act as
alarm signals of cardiac distress56. Murray et al have shown that SCS for refractory
angina is effective in preventing hospital admissions without masking the ischemic
symptoms or leading to silent infarction57.
The mechanisms of action of SCS are unclear. There may be homogenization of
myocardial blood perfusion with SCS and that this reduces myocardial ischemia44,58.
Another study has demonstrated that SCS improved heart muscle lactate metabolism and
oxygen demand and blood flow in the coronary sinus59. Other studies show that SCS
does not effect variability in heart rates or cardiac arrhythmias40,60,61. Hautvast et al. 62
demonstrated no significant changes in heart rate variability after 6 wks concluding that
heart rate variability via autonomic modulation may not be the explanatory mechanism of
action.
As the relation between pain and myocardial ischemia has not been fully clarified, we do
not know whether the pain relief is due to direct depression of the nociceptive signals in
the spinal cord or whether there is secondary gain from a reduction in the ischemia63,64.
A significant amount of work by Foreman has shown that dorsal column stimulation
inhibits the activity of spinothalamic tracts cells evoked by activation of the cardiac
sympathetic afferents or by intracardiac bradykinin. On the other hand the effects of
stimulation might be equivalent to those of a sympathectomy and may act by producing a
prolonged inhibition of the hyperactive sympathetic system. Such mechanism has been
shown experimentally in the rat by Linderoth et al.52
The most appropriate electrode location for the treatment of angina pectoris is most likely
the lower cervical and upper thoracic region, although some have reported successful
higher cervical placements47. Another consideration is continuous versus cyclical use of
SCS. In practice, patients using SCS for angina pectoris often use a low intensity
stimulation for several hours per day for prophylactic purposes65. Recently, a
randomized control study demonstrated improvement in functional status and symptoms

in treatment arms with conventional or sub threshold stimulation in comparison to a low
output placebo treatment arm66. This is the first “blinded study” in which stimulation
below the sensory threshold for parasthesia demonstrated therapeutic efficacy eliminating
the possibility of a placebo effect.
The success of the procedure ultimately will be determined by the cardiologists.
Questions exist as to the actual number of patients who despite all treatment modalities
(including coronary bypass) continue to have symptoms of such magnitude as to require a
spinal cord stimulator. Similar to the indication for peripheral vascular disease, European
physicians have demonstrated a substantially greater interest in the modality that US
physicians. As with other applications, a substantial amount of data from well-controlled
clinical studies will be necessary before the procedure will be fully endorsed by the
medical community in the US.
Chronic critical limb ischemia (CCLI) and Pain
Cook et al. were the first to suggest in 1973 that the indications for SCS might extend
beyond intractable pain control67. They observed a group of patients with multiple
sclerosis who underwent SCS to treat their chronic pain. Unexpectedly, the patients
experienced not only pain relief but also an improvement in mobility as well as sensory
and bladder function. Cook et al. noted apparent improvement in lower limb blood flow
and subsequently used SCS in patients whose primary problem was peripheral vascular
disease(PVD)68. He demonstrated relief of rest pain, increased skin temperature,
improved plethysmographic blood flow and healing of small cutaneous ulcers.
Subsequently, Meglio and Cioni in 1981 reported pain relief and ulcer healing in a patient
with advanced peripheral arterial insufficiency69. In 1988, Jacobs published clinical
evidence that SCS improved the micro-circulation as measured by capillary
microscopy70.
Klomp et al. 71 randomized 120 patients, with critical painful limb ischemia, to receive
either best medical therapy alone or SCS in conjunction with best medical therapy. At a
mean follow-up of 19 months, there was no significant difference in pain score

improvement between the two groups. Jivegard et al. 72 also reported on a similar study
where 51 patients were randomized to receive either oral medication alone or SCS with
oral medication. Conversely, they reported a significant improvement in pain scores of
the SCS treated group over the non-SCS group (p<0.01).
Four prospective studies without matched controls (references?!?) in the literature reveal
an overall success rate of 78% (n=271). Analysis of seven retrospective studies found an
overall success rate of 76% (n=308)29. A review of the European literature demonstrates
that 70-80% of patients achieved significant (>75%) pain relief. Many other large studies
have been reported on the long term results of SCS on pain and ulcer healing73-78.
In a prospective randomized trial by Guarnera et al. the effectiveness of SCS compared to
distal arterial reconstruction was evaluated and demonstrated a more favorable outcome
in SCS (72%) compared to distal arterial reconstruction (40%) 79 . In a Cochrane review
looking at six studies of SCS versus conservative treatment, it was determined that limb
salvage after 12 months was significantly higher in the SCS group, and significant pain
relief occurred in both treatment groups, but was more prominent in the SCS group80.
The mechanisms of action are unclear. The most likely mechanism responsible for
increased blood flow in subjects with peripheral vascular disease is inhibition of the
sympathetic system. This phenomenon occurs within the spinal cord at the local level
and is not related to antidromic activation of afferents fibers. Supra-segmentary
influence on medullary vegetative centers does not need to be invoked. The possible role
of locally released vasoactive peptides is still awaiting elucidation. Whether the effects
on pain and blood flow are due to the same mechanisms is unknown, although some
evidence suggests that pain relief is secondary to the microcirculatory changes. Multiple
mechanisms may be operating simultaneously81-85.
Abdominal/Visceral Pain Syndromes
Approximately 20% of the population in United States has abdominal pain. There are
many etiologies for abdominal pain including gastrointestinal, genitourinary,
musuloskeletal and nervous systems. Treatment modalities have included cognitive-

behavioral, physical, and pharmacological therapies. Other more invasive therapies have
extended to include celiac plexus blocks and celiac ganglia destruction. Some studies
have demonstrated some localization in the spinal cord for visceral pain secondary to
malignancy. Midline myelotomy through the dorsal columns at the level of T10 has
shown success in eight patients with refractory pelvic cancer pain. This was also
demonstrated in animal studies where dorsal column activity was observed in pelvic
visceral nociception 86.
Initially there was lack of evidence for the application of spinal cord stimulation for
visceral and somatic pain secondary to the belief that nociceptive pain could not be
modulated via stimulation. Several initial studies have since demonstrated the benefit of
SCS in abdominal visceral disease. Ceballos et al. 87 demonstrated reduction in pain
scores and decrease in narcotic use in a patient treated for mesenteric ischemia. Trial
stimulation was 13 days with implantation followed for 12 months with the electrode
placed at T6. The patient had only two small pain recurrences in that period, one of which
was when the stimulator was stopped. Krames et al. 88 described a patient treated for
irritable bowel syndrome who was developing escalating pain and diarrhea. Although the
pain treatment eventually required intrathecal therapy there was a significant reduction in
the amount of diarrhea. The patient underwent a two week trial and subsequently had
implantation at the T8 level. In the first 6 months there was a subjective decrease in pain
form 9/10 to 2/10 with only two diarrhea episodes and significant reduction in pain
medications. There was some return of pain after ten month follow up requiring increase
in pain medications, but still remained with significant reduction in diarrhea.
Khan et al 89 reported on the largest series with nine patients with refractory abdominal
pain. Five of the nine patients had nonalcoholic pancreatitis, three had presumed
abdominal wall neuromas from frequent abdominal surgery, and another had post
splenectomy pain after trauma. All patients had a significant improvement in VAS scores
as well as decreased narcotic use with placement of the leads at the T5-7 level at six to
eight month follow up.

Tiede et al. described treatment of refractory abdominal pain in two patients. Both
patients had a significant history including multiple abdominal surgeries and failed
conservative measures. Each patient had an element of postprandial abdominal pain with
associated nausea and vomiting. In both patients the leads were placed at the T2 level
with significant improvement in pain, decreased narcotic use and increase functioning,
such as return to work90. Kapur et al. 91 recently described relief of abdominal pain
associated with colchicine intolerant or resistant patients with familial Mediterranean
fever by placement of the electrodes at the lower thoracic levels.
More recently studies have looked at the treatment of visceral pelvic pain with reference
to the dorsal columns and spinal cord stimulation. Kapural et al 92 reported on the value
of neurostimulation for chronic visceral pelvic pain in six female patients with the
diagnosis of long- standing pelvic pain. These patients had a history of endometriosis,
multiple surgical explorations, and dyspareunia. At an average follow up of 30 months
there was a significant decrease in the VAS score with an average of more than 50% pain
relief, with a decrease in opiate use.
Visceral innervation follows the embryologic origin and location of the viscera and is
arranged in viscerotomes, analogous to cutaneous dermatomes 93. The viscera obtain their
innervation via the sympathetic and parasympathetic pathways. The parasympathetics
carry their afferents to anterior and posterior vagal trunks and are therefore not as
amendable to spinal cord stimulation. The sympathetics carry nociceptive information
from the viscera to spinal nerve roots making them a more viable target. The sympathetic
afferents in the lower six thoracic and the upper three lumbar spinal segments have been
shown to transmit painful impulses from the viscera94.
Brachial Plexitis/Neurogenic Thoracic Outlet Syndrome
Spinal cord stimulation has also been described for pain secondary to either brachial
plexitis or neurogenic thoracic outlet syndrome. Most of these patients complain of pain
which affects the upper extremity, the shoulder, the trapezius, the axilla, and/or the
anterior upper chest wall. With the currently available systems, stimulation of all areas is

often not feasible with a single electrode. Stimulation of the shoulder and the whole
upper extremity requires an electrode placement in the upper cervical area. Stimulation
in the axilla and upper chest wall area, instead, might be achieved only with an electrode
in the lower cervical/upper thoracic area. Only occasionally an upper cervical placement
will reach all of the above-mentioned areas. In the more common scenario, two
electrodes are necessary in order to obtain the appropriate coverage. Further, a two
channel stimulating device might be indicated, since the setting for the upper cervical
region can be different from the one required to optimally stimulate the axilla and
anterior chest area. One specific challenge with these patients is in the extreme
hyperesthesia present in brachial plexus region as well as in the trapezius, often extending
to even larger areas of the posterior thorax. Any surgical manipulations in these areas of
hypersensitivity must be avoided at all cost. Tunneling of the implanted wires must be
planned carefully and must be at a substantial distance from the hypersensitive area.
Lack of adherence to these principles often results in excruciating pain and intolerance to
the implanted system. Unfortunately, literature is relatively lacking for this indication.
Relevant Anatomy
Understanding the somatotopy of the spinal cord is paramount to knowing the technical
aspects of implantation. A basic tenet of SCS is to create an overlapping of paresthesia
and pain region. In order to do this, correlation of the somatotopy and the level of the
spinal cord is necessary. Barolat has published extensively on the mapping of the spinal
structures in man. A database was created to suggest areas of sensory response to dorsal
spinal cord stimulation95.
High cervical regions such as C2 can cover the posterior occipital region, and
occasionally the lower jaw. C2-4 stimulation will provide coverage of the shoulder while
stimulation in the lower cervical region such as C5-6 will provide for the entire hand. To
cover the anterior chest wall or the axilla, an electrode towards C7 will be necessary.
More commonly, an implanter will seek cover the lower extremities. Lateral placement at
T11-12 will cover the anterior thigh, while placement at T11-L1 can cover the posterior

thigh. Coverage off the foot as a whole can be achieved along these same areas but it
becomes more difficult to cover the sole of the foot. Alternatively for coverage of the
sole of the foot, a patient may require insertion on the lumbar L5 or S1 nerve roots. Low
back pain is very difficult to cover because mid- thoracic stimulation can affect the chest
and abdominal wall. The experience of the author had best localization with midline
placement at T8-9.
Finally, most patients prefer stimulation of the dorsal column from electrodes closer to
the midline. Laterally, placed thoracic electrodes are more likely to stimulate the thoracic
nerve roots and result in painful stimulation.
Equipment (Electrodes and pulse generators)
The implanting physician should become familiar with the various implantable
technologies existing for SCS. These include trial percutaneous electrodes, permanent
percutaneous electrodes, permanent plate electrodes, totally implantable rechargeable and
non-rechargeable pulse generators (IPG) and radiofrequency (RF) driven pulse
generators.
Percutaneous electrodes
Percutaneous electrodes (or wire electrodes) are particularly appealing. Percutaneous
electrodes can be inserted without much dissection and offers a substantial advantage
when one performs a trial to assess candidacy for a permanent implant. After the trial
period, the temporary percutaneous electrode can easily be removed in the implanting
physician’s office. During implantation, these electrodes can be advanced over several
segments in the epidural space, allowing testing of several spinal cord levels to assess for
optimal electrode position.
Contemporary percutaneous electrodes are slim electrodes, which are only a few
millimeters in diameter and contain between 4-8 contacts with various spacings. (These
are referred to as either quadripolar or octopolar electrodes.) Choosing the particular
electrode entails deciding how many segments of the spinal cord are to be covered, with

larger spacing allowing broader coverage. Alternatively, closer spacing allows better
steering and electric field shaping. Additionally, multiple parallel electrodes and different
configuration matrices can be constructed which can create extremely focused electrical
fields. The general trend is to utilize one or two quadripolar electrodes for limb pain and
one or two octopolar electrodes for axial pain. Even insertion of three electrodes is being
explored for better steering of current33. These percutaneous electrodes also come in
varying lengths and these differ by manufacturer. At times, extensions cables will be
necessary to bridge the distance from the spinal entry point to the pocket in which will
reside the battery.
The technique of percutaneous implantation.
The patient is positioned in a comfortable prone position on a fluoroscopy table. A
pillow underneath the abdomen may create some kyphosis which might facilitate
electrode insertion.
The level of electrode insertion is guided by several factors. A fundamental
consideration is that several centimeters of the lead have to lie in the epidural space to
assure maximal stability of the electrode and minimize unwanted migration. To assure
this, insertion must take place at least two spine segments below the desired target. For
cervical placement, one must be aware of the cervical cord enlargement and when
possible, electrode insertion should be performed below the T1-2 level. Some surgeons
advocate upper thoracic placement of percutaneous electrodes through a limited spinous
process removal, in order to minimize the potential risk of spinal cord damage. For
practical purposes, implantation for low back problems necessitates electrode insertion at
T12-L1 or L1-2 while implantation for an upper extremity target requires insertion at T23 or T3-4.
The fluoroscopy equipment must be ready to function in both the antero-lateral and
lateral planes at the time of needle insertion. The Touhy needle is inserted with as
shallow an angle as possible. While in the thoracic area this can be accomplished with

either a midline or paramedian approach, in the upper lumbar area a paramedian approach
is required. A steep angle increases the risk of electrode fracture.
Several methods are available to identify the epidural space. The tactile feedback is
important but cannot be solely relied upon. The most common method is the loss of
resistance using a low-friction glass syringe. We prefer to inject a small amount of air.
Fluid injected in the epidural space may later be aspirated through the needle and give the
false impression of being in the subarachnoid space. After multiple passes at one spine
level have been performed, the loss of resistance method may loose its reliability.
Inserting a Seldinger wire through the needle can provide invaluable information as to the
degree of penetration into the spinal canal. If the needle tip is in the interspinuous
ligament and has not penetrated the ligamentum flavum, the wire cannot be advanced.
The wire can be advanced only if the needle tip is in the paraspinal muscles or within the
spinal canal. The pattern of advancement and the location of the wire under fluoroscopic
imaging can further clarify its position.
Once the electrode is in the spinal canal, one has to be certain that it is positioned in the
epidural space and not within the subarachnoid space. Even though this may seem
obvious and easily recognizable, this may become a very difficult task and require
multiple attempts at needle placement. This is particularly true if the arachnoid has been
previously pierced and CSF has escaped and pooled in the dorsal epidural space. In the
subarachnoid space, much less resistance is encountered when moving the electrode,
particularly for lateral movements. The wire seems almost to be "floating" and
undergoes large shifts of direction, where in the epidural space, movements are more
discrete and obtained only with specific manipulations. The same type of wire/electrode
movement can however be experienced epidurally if the dural sac has significantly
collapsed secondary to CSF loss. Electrical stimulation will clarify the position, as a
subarachnoid placement can elicit motor or sensory responses at much lower thresholds
than epidural placement.
When the epidural space is satisfactorily identified, the electrode is gently inserted under
fluoroscopic guidance in the antero-posterior view. Removal of the electrode once it has

been inserted through the tip of the needle has to be accomplished without insulation with
the electrical contacts. If the electrode does not slide without minimal resistance, the
needle and the electrode should be removed together. Every time the electrode is
withdrawn through the needle, it should be inspected for minute breaks in the insulation,
which would necessitate its disposal. Alternatively, a sleeve can be inserted over the
guide wire in the epidural space. The guide wire is then removed and the electrode is
inserted through the sleeve. This obviates the risk of shearing the electrode during
manipulation. The electrode is then steered in the epidural space to the desired location.
Should the targeted location prove to be less than two spinal segments from the electrode
insertion, the electrode should be withdrawn and repositioned at a more caudal level.
Frequently, the electrode curves around the dural sac and ends in the ventral epidural
space. In the antero-posterior projection this might be indistinguishable from a proper
midline dorsal location. A gentle lateral curve of the electrode shortly after its entry in
the epidural space should arise the suspicion that it is directing ventrally around the dural
sac. Absolute confirmation of the ventral location arises from the stimulation generating
violent motor contractions or observation in the lateral plane which would readily
discloses the anterior position of the electrode tip. If more than one electrode is inserted,
it is wise to insert the other needles before inserting the electrodes. Needle insertion
might shear an already implanted electrode. Besides, it is often possible to insert two
electrodes simultaneously and advance them synchronously in the epidural space while
maintaining their relative position and spacing.
Once in place, the electrode must be secured to the interspinous ligament to minimize
dislodgment. An X-ray is obtained to document electrode level and position. We have
found that securing loops at the electrode insertion site serves to relieve the strain and
reduces migration during bending. Frequently, anchors are used to secure the electrode
and the implanter should remember that anchoring is a two step process: 1. Securing the
anchor to the electrode. 2. Securing the anchor to the fascia. At present, there is only
one anchor available which has the ability to be detected on radiographs, the TITAN
anchor (Medtronic, Inc, Minneapolis, MN) (Figure 1)

A major disadvantage that has been cited with percutaneous electrodes is their tendency
to migrate. This is related to their inherent flexibility, which is necessary for their
insertion through a Touhy needle, and to their cylindrical shape, which does not prevent
migration even months after implantation. Some percutaneous electrodes require a
stiffening stylet for introduction. Also, percutaneous electrodes are less energy efficient
that plate electrodes. The electrical current is distributed circumferentially around the
electrode and is expected to result in greater shunting of current. Patients with
percutaneous leads also describe a greater positional variance in their paresthesia.
Recently ANS (ANS – A St. Jude company, Plano, TX) has introduced a slim-line plate
type electrode, which can be inserted percutaneously. The broader electrode base
provides a surface where fibrosis should lessen the risk of caudal electrode migration.
The slimmer profile of the electrode might also have advantages in the cervical spine
where spinal cord compression might be an issue. Finally, the design emulates that of a
mini-plate lead as the contacts are on one side with the other side being insulated. This
will definitely be more energy efficient than a percutaneous lead which would allow
delivery of current circumferentially. (Figure 2)
Plate electrodes
Plate-type electrodes (or ribbon electrodes, paddle electrodes, or laminotomy electrodes)
require a surgical procedure, laminotomy, and implantation under direct vision(28).
Implantation under direct vision may be safer in the upper thoracic and cervical areas,
where there is a risk of damaging the spinal cord with the large bore Touhy needle. Most
implants can be done through a skin incision between 2.5 – 4 cm long, depending on the
size of the patient and spinal anatomy. The amount of bony removal is usually minimal
Multiple arrays or different electrode configurations can be also constructed with plate
electrodes. The main advantage of plate electrodes resides in their more inherent stability
in the dorsal epidural space and lesser propensity to migrate. Some preliminary data by
North also suggest a broader stimulation pattern and lower stimulation requirements with
plate electrodes96. Plate electrodes are more energy efficient in delivering electrical

stimulation. We advocate plate electrodes as the only option in the case of previous spine
surgery at the implant levels.
Plate electrodes come in many sizes, shapes, spacing, and configurations. There are
single column and dual column electrodes. As with percutaneous leads, there are varying
lengths, and shapes – such as curved leads and hinged leads, all designed to help facilitate
insertion and tailor the electrode selection to the patient.
There is some literature describing the advantages of plate leads. North et al have
published on comparison between plate and percutaneous electrodes96. Laminectomy
electrode placement, although more invasive than percutaneous placement, yielded
significantly better clinical results in patients with failed back surgery syndrome at up to
3 year follow up. Clinical success was defined as at least 50% pain relief and patient
satisfaction with treatment. Secondary outcome measures were ability to perform various
activities of daily living, neurological function, and analgesic use. There is some
theoretical evidence that shaping of the electrical field is possible with even more
complex electrode arrays. Holsheimer et al 97 concluded that the transverse tripolar
system enabled finer control of paresthesia. Electrical field steering could change the
paresthesia area completely. When the transverse tripolar configurations are used, the
threshold for stimulation of dorsal roots is higher, compared with the dorsal column
threshold. This results in a wider therapeutic range, wider paresthesia coverage, and a
greater probability to fully cover the painful area with paresthesia.
One must bear in mind, that with the increasing number of contacts, there is a significant
increase in power consumption and the complexity of programming rises in even a
greater magnitude. With two contacts, the total number of configurations possible are
eight, with four contacts, sixty-four; and with eight and with sixteen contacts, it increases
exponentially to reach a number in the millions.

Two basic positions can be utilized: prone or semi-lateral. The prone position allows a
more intuitive understanding of the spatial relations and is one that more surgeons are

familiar with. In this position, it can be difficult to obtain adequate sedation for the
surgical exposure and maintain the airway. In the semi-lateral position, the patient lies
comfortably in a park bench type position, allowing access to the spine as well as the
flank, abdomen, or buttock for the implant of the pulse generator. The patient is asked to
place him/herself in the most comfortable position. If the pain is predominantly on one
side, the patient is asked to lie on the less affected side. In this position, airway
management is safer than in the prone position and the anesthesiologist is more
comfortable in keeping the patient deeply sedated. Given the variable degree of rotation
of the body, it can be difficult for the surgeon to determine the location of the midline.
This might constitute a significant problem in the cervical area.
Strategies at different spine levels
The planned level is localized either with fluoroscopy or with a plain X-ray with metallic
markers placed on the skin at the level of the planned incision. In a thin individual the
incision is about one inch in length; even in large individuals, the incision seldom needs
to be more than two inches long. Different considerations apply if one is implanting
through a previously operated on level.
For cervical placement, the patient is placed in the semi-lateral position with the neck
slightly flexed. Even with a short skin incision one can reach 3-4 levels by extending the
inside dissection and stretching the skin edges with a Gelpi retractor. The neck should be
flexed but not excessively rotated laterally. Even though some neck rotation is
inevitable, extreme rotation substantially increases the level of difficulty.
Subperiosteal dissection is usually limited to the upper half of the spinous process
inferior to the addressed ligamentum flavum and to the whole spinous process superior to
it. Parts of the superior spinous process are incrementally removed until the ligamentum
flavum is exposed. In the lower thoracic/upper lumbar area this usually resulted in
removal of inferior 1/3 rd of the spinous process. In the mid-thoracic area, due to the
acute angle and significant overlapping of the spinous processes, the whole spinous
process must be removed. Following removal of the ligamentum flavum, the electrode(s)

is inserted in the dorsal epidural space; the electrode position is then confirmed with
fluoroscopy and testing is performed with either motor stimulation or with the patient
awakened and, when mentally lucid.
Alternatively, the electrode can be placed with the patient fully in the prone position.
Flouroscopy should be used to identify the same level where the active contacts were
placed during the trial. A laminotomy is performed approximately one level below this
point as allow the plate electrode to reach up to the intended level. After placing the
electrode, intra-operative stimulation with electromyographic correlation will be able to
detect stimulation in the extremity and lateralization of the electrode. We stimulate the
electrode with 5 Hz stimulation at greater than 310 us pulse width and ramp up the
amplitude until EMG signal changes are detected. Bilateral extremity stimulation
suggests midline placement and early root onset implies too lateral a placement. We
have had instances in which the physiological midline differed form the anatomic midline
and we will be more apt to rely on the intra-operative physiology in those instances.
When treating, axial symptomatology, the lead is placed to straddle the midline. For
patients with unilateral pain, the lead is placed so that one array is on the side of the pain
and the other is on the midline.

Rechargeable and non-rechargeable Pulse Generators and Radio-Frequency
Receivers (Figure 3)
Electrical stimulation consists of rectangular pulses delivered to the epidural space
through implanted electrode via a power source. Two basic types of systems are currently
available: an Internal Pulse Generator (IPG; also called the battery.) or a radiofrequency
(RF) coupled pulse generator with an implantable receiver. The later has largely fallen
out of favor due to the inconveniences of having an external power source. However, the
advent of the totally implantable, rechargeable pulse generator has surmounted the power
requirement issues, which were previously, the real RF advantage.

The totally implantable pulse generator contains a lithium battery. Activation and control
occur through an external transcutaneous telemetry device. The IPG can be turned on
and off through a small controller which the patient can carry. The controller also allows
some control over the stimulation parameters. More extensive control of the unit can be
achieved through a small portable unit which can be programmed by the physician.

Life

span of the battery varies with usage and with the utilized parameters (voltage, rate, pulse
width, etc.). Most patients can expect, under average usage, that the battery last between
2.5 to 4.5 years. Available lithium powered pulse generators allow stimulation with fine
resolution increments of 0.05 V and with varying rates and pulse widths. Replacement of
the battery requires a surgical procedure which is usually performed on an outpatient
basis.
A particular IPG is selected based on many variables. From a practical standpoint, the
first and foremost reason might be the size of the patient. Although larger batteries will
have longer life, the site of insertion of the IPG (either the buttock, abdomen, or the
subclavicular region) is often the source of significant patient complain. (We prefer to
implant the IPG in the buttock because of the ease associated in tunneling from the
electrode insertion. Further, with a patient placed prone for electrode insertion, there is
no repositioning required to reach the buttock region. We identify boney prominences
including the posterior superior iliac crest, the greater trochanter of the femur, and the
apex of the iliac crest and implant the IPG in the lateral aspect of this triangle. (Figure 4)
Radio frequency (RF) driven systems, consist of a passive receiver, implanted
subcutaneously, and a transmitter which is worn externally. An antenna applied to the
skin in correspondence of the receiver is connected to the transmitter ,which sends the
stimulation signals transcutaneously. In order for the system to function, the transmitter
has to contain charged alkaline batteries and the antenna must make adequate contact
with the receiver. This requires the patient to wear the external system in order to receive
the stimulation. RF driven systems can deliver stimulation with rates up to 1,400 Hz, and
can be customized to deliver high power levels. RF systems have the inconvenience of
having to wear the antenna and the radio-receiver. The problem might go beyond pure
inconvenience in individuals who have handicapped motor function in the upper

extremities and cannot properly go through all the steps required to make the external
unit function properly. Other patients, particularly individuals who have reflex
sympathetic dystrophy (RSD), may not tolerate the antenna taped to the skin. Obtaining
adequate contact of the receiver with the skin may be difficult secondary to swelling at
the site. The equipment cannot be worn while swimming or showering, and severe
perspiration, as with exercise and physical therapy, might make proper contact of the
antenna problematic. Furthermore, the patient has to replace batteries on a regular basis
and make sure that proper coupling exists between the antenna and the receiver at all
times. However, what one loses in convenience, however, is gained in power and
flexibility. Currently only RF systems can provide a stimulation rate up to 1,400 Hz.
This might be beneficial in some patients with neuropathic chronic pain syndromes98, as
well as in patients with extrapyramidal motor disorders .
Rechargeable systems have now become available. Medtronic’s device, known as the
Restore Rechargeable Neurostimulation System, uses a battery with an estimated nineyear total life span. It takes about six hours to fully recharge the batteries. The
Advanced Neuromodulation Systems’ Eon device has a battery life that is currently
estimated at seven years. Boston Scientific’s Precision device has a battery life estimated
at five years. A detailed comparison of the features of the rechargeable batteries are seen
in Table 1.
Complications
With the proper expertise, permanent complications are rare70. The most serious
complication, which is shared with any type of spine surgery, is paralysis or any severe
neurological deficits. This can occur during spinal cord stimulation procedures, both with
percutaneous and plate electrodes. Infection of the implanted hardware has occurred with
a 3-5% rate. Persistent pain at the implant site has been seen in about 5% of patients.
Recalcitrant cerebrospinal fluid leakage has been encountered in a few patients, requiring
multiple surgical revisions. Breakage or malfunction of the implanted hardware,
particularly the electrodes and the subcutaneous extension cables has been encountered in

about 10% of the implanted systems. Painful stimulation, necessitating either
repositioning or removal of the electrode, has also been reported in a number of cases.
Conclusions
The treatment of chronic pain remains challenging. Spinal cord stimulation has been
performed for over 30 years, and slow but steady progress with this technology has been
made. As the equipment and stimulation parameters are improved, selection criteria has
been better defined and is slowly being expanded. More importantly, experience in the
technique and the equipment has made SCS a much more reliable and safe modality.
Like all the modalities performed for chronic pain management, its results are favorable.
It is important to remember that the goal of neurostimulation is to reduce pain, rather than
to eliminate pain. It has been shown to have a 50% improvement in pain relief. Very few
other invasive modalities can claim this success rate with a few years of follow-up
Careful follow-up of the patients is necessary for successful long-term satisfaction.
Equipment related problems can arise at any time after implantation, such as discomfort
at the pulse generator/radio receiver site, electrode(s) breakage or migration, infection,
etc., and an open dialogue with the patients is vital for the continuing successful
implementation of the modality. Spinal cord stimulation has earned a well established
and firm role in contemporary chronic pain management.

Figure 1: Titan Anchor – (Medtronic Inc. Minneapolis, MN)
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Figure 3: Rechargeable batteries.

Table 1: Comparison on Rechargeable Batteries

Volume (cc)
Dimensions
Weight (g)
Stimulation output
Amplitude
Frequency
Pulse Width
Battery Capacity
Rechargeable
Wireless communication
Maximum Recharge
Depth

Precision Plus

Restore Advanced

Eon

22

39

42

55 x 45 x 11

65 x 49 x 15

59 x 58 x 16

36
Multiple current
sources

72

75

Constant voltage

Constant current

0 - 20 mA

0 - 10.5V

0 - 25.5 MA

2 - 1200 Hz

2 - 130 Hz

2 - 1200 Hz

20 - 1000 us

60 - 450 us

50 - 500 us

200 mA hr

300 mA hr

325 mA hr

Cordless

Cordless

Connect to Outlet

up to 30 inches

up to 4 inches

N/A

2 cm

1 cm

2.5cm

Figure 4: Battery Placement
The following is our described technique for the placement of the battery in the buttock
region. The boney prominences are marked: the greater trochanter/lateral femur, the
apex of of the iliac crest, and the posterior superior iliac spine (PSIS). A triangle is
created and the battery incision is made paralle to the top rung of the triangle.
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